Breaking News Instant updates and real-time market news.

AVGO

Broadcom

$262.84

9.06 (3.57%)

, QCOM

Qualcomm

$62.81

-0.22 (-0.35%)

09:09
03/13/18
03/13
09:09
03/13/18
09:09

On The Fly: Pre-market Movers

HIGHER: Broadcom (AVGO), up 1.5% after President Trump issued an order blocking Broadcom's attempt to acquire Qualcomm (QCOM). Intel (INTC) shares are also up 2% following the news... Proteostasis Therapeutics (PTI), up 48% after announcing that the FDA has granted Breakthrough Therapy Designation for PTI-428, the company's cystic fibrosis transmembrane conductance regulator amplifier... Altice USA (ATUS), up 5% after Goldman analyst Brett Feldman added Altice USA to the Conviction Buy List. LOWER: Qualcomm, down 5.4% after President Trump blocked Broadcom's acquisition attempt... Advaxis (ADXS), down 21% after a clinical hold was placed on the Phase I/II combination study of axalimogene filolisbac with IMFINZI for the treatment of patients with certain types of cervical cancer and HPV-associated head and neck cancer... Myriad Genetics (MYGN), down 8.5% after the company disclosed it recently received a subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid. DOWN AFTER EARNINGS: Dick's Sporting Goods (DKS), down 5%... Stitch Fix (SFIX), down 5.5%.

AVGO

Broadcom

$262.84

9.06 (3.57%)

QCOM

Qualcomm

$62.81

-0.22 (-0.35%)

INTC

Intel

$51.52

-0.67 (-1.28%)

PTI

Proteostasis

$4.14

0.02 (0.49%)

ADXS

Advaxis

$2.21

0.01 (0.45%)

DKS

Dick's Sporting

$32.56

0.64 (2.01%)

MYGN

Myriad Genetics

$33.02

0.45 (1.38%)

SFIX

Stitch Fix

$24.12

1.55 (6.87%)

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 15

    Mar

  • 18

    Mar

  • 23

    Mar

  • 23

    Mar

  • 23

    Mar

  • 29

    Mar

AVGO Broadcom
$262.84

9.06 (3.57%)

03/13/18
BNCH
03/13/18
NO CHANGE
BNCH
Buy
Marvell-Cavium deal in focus after denial of Broadcom-Qualcomm, says Benchmark
After President Trump signed an order prohibiting Broadcom's (AVGO) attempt to take over Qualcomm (QCOM), Benchmark analyst Gary Mobley said the news may cause investors to question CFIUS approval for the planned tie-up of Marvell (MRVL) with Cavium (CAVM). It is possible Marvell may have to re-domicile in the U.S. from Bermuda, which may delay the merger by a few months and would increase Marvell's tax rate unfavorably, he said. Mobley, who think it is hard to say whether the President will shoot down the deal, noted that CFIUS and China's MOFCOM are the last two regulatory hurdles for Marvell and Cavium's deal. He has a Buy rating on Marvell shares.
03/13/18
ADAM
03/13/18
NO CHANGE
Target $86
ADAM
Buy
Qualcomm weakness a buying opportunity, says Canaccord
Canaccord analyst T. Michael Walkley noted the White House blocked the takeover of Qualcomm (QCOM) by Broadcom (AVGO) in the interest of national security. He expects the shares of Qualcomm to be weak as a result and recommends investors buy the shares on the pullback. He left his estimates and price target the same and believes its valuation will be compelling, especially if it closes the NXP Semiconductor (NXPI) deal. Walkley reiterated his Buy rating and $86 price target on Qualcomm shares.
03/13/18
RHCO
03/13/18
NO CHANGE
Target $335
RHCO
Broadcom price target lowered to $335 from $344 at SunTrust
SunTrust analyst William Stein lowered his price target on Broadcom (AVGO) to $335 after the company's bid for Qualcomm (QCOM) came undone. Stein says the new price target is based on Broadcom's stand-alone valuation and potential accretion from another medium-sized deal, forecasting the company to pursue another target "in due time". The analyst keeps his Buy rating on Broadcom, adding that M&A has been a "massive driver" of its earnings growth.
QCOM Qualcomm
$62.81

-0.22 (-0.35%)

03/12/18
BMOC
03/12/18
NO CHANGE
Target $345
BMOC
Outperform
Broadcom price target raised to $345 from $330 at BMO Capital
BMO Capital analyst Ambrish Srivastava raised his price target on Broadcom (AVGO) to $345 citing his new FY18 EPS target of $5.10 based on the company's revised guidance in January. Srivastava keeps his Outperform rating going into the next earnings update, noting that fundamentals for Broadcom remain "strong" even as much of the investor focus is around its bid for Qualcomm (QCOM). The analyst forecasts Broadcom Wireless Communications segment to grow 10% on the quarter and Enterprise Storage segment to grow 40% on the quarter.
INTC Intel
$51.52

-0.67 (-1.28%)

02/26/18
NOMU
02/26/18
NO CHANGE
Target $60
NOMU
Buy
Intel price target raised to $60 from $50 at Nomura Instinet
Nomura Instinet analyst Romit Shah raised his price target for Intel to $60 citing higher estimates and multiple expectations. The analyst notes the company's Datacenter Group revenue exceeded Street expectations for the second consecutive quarter in Q4, growing 20% year-over-year. He believes the growth is sustainable.
03/07/18
KEYB
03/07/18
NO CHANGE
KEYB
KeyBanc remains a buyer of Intel, Marvell
In a research note titled "Notebook ODM tracker," KeyBanc analyst Michael McConnell says February unit shipments are likely to be modestly below his estimates, but is maintaining his Q1 unit shipment estimate of -18% quarter over quarter. McConnell remains a buyer of Intel (INTC) due to its processor sell-in, and signs of improving commercial demand. The analyst also remains constructive on Marvell (MRVL) due to higher confidence on revenue growth, driven by the networking and SSD controller segments, design-win traction and sales momentum into data centers, and higher networking and data center sales mix, gross margin accretion, and multiple expansion from the pending Cavium (CAVM) acquisition.
02/27/18
SBSH
02/27/18
NO CHANGE
SBSH
Buy
Citi calls Intel the Micron of 2018, moves to top Semi pick
Intel (INTC) is one of the only Semiconductor stocks with poor investor sentiment given its valuation discount to peers and the stock's underperformance year-to-date, Citi analyst Christopher Danely tells investors in a research note. The analyst believes the recovery in the enterprise end market will drive consensus estimates higher. Intel's combination of "very low" sentiment and "substantial" upside to consensus estimates is similar to Micron (MU) in 2017, Danely contends. The analyst moves Intel to his to pick in Semiconductors.
02/26/18
BARD
02/26/18
NO CHANGE
Target $60
BARD
Outperform
Intel indicating strong growth outlook for 2018, says Baird
Baird analyst Tristan Gerra said Intel's Data Center Group growth could accelerate this year versus last year, fueled by continued strong demand while Xeon Scalable's adoption rate continues to increase. The company also sees a strong second half 2018 outlook for CCG as its momentum will be driven by a sharp rebound in iPhone units and the company's significant share gain. Gerra reiterated his Outperform rating and $60 price target on Intel shares.
PTI Proteostasis
$4.14

0.02 (0.49%)

12/12/17
JMPS
12/12/17
NO CHANGE
Target $200
JMPS
Outperform
Proteostasis data not as positive as Vertex, says JMP Securities
JMP Securities analyst Liisa Bayko says Proteostasis Therapeutics' (PTI) CF programs look positive, but not as positive as Vertex (VRTX) at this point. Nonetheless, the analyst acknowledges that it remains early days for Proteostasis and she still needs to see how its internal triple combination will perform. Bayko reiterates an Outperform rating and $200 price target on Vertex shares.
12/12/17
LEER
12/12/17
NO CHANGE
Target $8
LEER
Proteostasis price target raised to $8 from $6 at Leerink
02/13/18
HCWC
02/13/18
NO CHANGE
Target $107
HCWC
Neutral
Vertex halted trials in France as protest, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein says he learned via Twitter and a news article that Vertex Pharmaceuticals (VRTX) decided to discontinue the Phase 3 trials of its triple combination therapy for cystic fibrosis in France due to an inability to reach reimbursement agreement with the French authorities for Orkambi. Releasing patients may inadvertently help Vertex's competitors gain ground, especially Galapagos (GLPG) and Proteostasis (PTI), Fein tells investors in a research note. He keeps a Neutral rating on Vertex shares with a $103 price target.
03/09/18
RBCM
03/09/18
INITIATION
Target $11
RBCM
Outperform
Proteostasis initiated with an Outperform at RBC Capital
RBC Capital analyst Bryan Abrahams initiated Proteostasis with an Outperform rating and a price target of $11, saying the company is one of only 3 players "with multiple clinical-stage modulators of the CFTR channel, dysfunction of which causes the disease which are in early/mid-stage trials as monotherapy and combos", creating "scarcity value" in the market. Abrahams is positive on Proteostasis suite of cystic fibrosis assets, with promising preclinical signals and multiple opportunities in 2018 readouts.
ADXS Advaxis
$2.21

0.01 (0.45%)

03/13/18
CANT
03/13/18
NO CHANGE
Target $5
CANT
Overweight
Advaxis price target lowered to $5 from $19 at Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein lowered his price target for Advaxis to $5 after a clinical hold was placed on the Phase I/II AXAL plus durvalumab trial. The analyst, however, thinks it is "very possible" that the hold will be resolved. Further, Advaxis has sufficient capital into 2019, which is a "counterpoint to the clinical hold," Goldstein tells investors in a research note. She keeps an Overweight rating on Advaxis shares.
DKS Dick's Sporting
$32.56

0.64 (2.01%)

03/12/18
JPMS
03/12/18
NO CHANGE
Target $43
JPMS
Overweight
Dick's Sporting setup favorable into tomorrow's results, says JPMorgan
JPMorgan analyst Christopher Horvers believes Dick's Sporting Goods' favorable 2018 setup is intact going into the company's Q4 results on March 13. The analyst sees downside risk to $28-$29 per share and upside potential to $43. Street 2018 estimates make for a positive catalyst on earnings, Horvers tells investors in a pre-earnings research note. He keeps an Overweight rating on the Dick's Sporting with a $43 price target.
02/07/18
JPMS
02/07/18
NO CHANGE
Target $43
JPMS
Overweight
Dick's Sporting risk/reward 'highly attractive,' says JPMorgan
JPMorgan analyst Christopher Horvers sees a "highly attractive" risk/reward in shares of Dick's Sporting Goods following the recent selloff. The analyst believes the Eagles Super Bowl win and new Little League bat regulations could provide a near-term lift in comp sales. He keeps an Overweight rating on Dick's with a $43 price target.
02/05/18
02/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Market Perform from Outperform at Keefe Bruyette, to Neutral from Buy at Citi, to Underperform from Outperform at RBC Capital, to Underweight from Neutral at JPMorgan, and two notches to Underweight from Overweight at Morgan Stanley. 2. Dick's Sporting (DKS) downgraded to Underweight from Equal Weight at Barclays with analyst Matthew McClintock saying sentiment on the shares have improved over the past month under the narrative that Dick's could become the next Best Buy (BBY). 3. Amgen (AMGN) downgraded to Neutral from Overweight at Atlantic Equities with analyst Steve Chesney citing relative valuation and more balanced risk/reward on Repatha's commercial trajectory and the of legacy biologics given biosimilar, branded and IP risks. 4. Marathon Petroleum (MPC) and MPLX (MPLX) were downgraded to Hold from Buy at Jefferies. 5. VMware (VMW) downgraded to Neutral from Buy at Citi with analyst Walter Pritchard saying he sees "no easy deal" for Dell and expects the overhang to cap VMware shares around the $138 level. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/21/18
OTRG
02/21/18
UPGRADE
OTRG
Mixed
Dick's Sporting upgraded to Mixed from Negative at OTR Global
MYGN Myriad Genetics
$33.02

0.45 (1.38%)

11/10/17
JPMS
11/10/17
NO CHANGE
Target $19
JPMS
Underweight
JPMorgan continues to see downside risk in Myriad Genetics
After conducting a survey of high-volume, U.S.-based psychiatrists to get a better sense of the traction GeneSight test is seeing and the longer term market opportunity, JPMorgan analyst Tycho Peterson continues to see risk to the downside in Myriad Genetics shares. Responses overall were mixed, with some indicating GeneSight provides meaningful clinical information while others were cautious on the utility of the test, Peterson tells investors in a research note. The analyst believes the failure of the GeneSight clinical utility study to hit the primary endpoint increases questions on Myriad's ability to gain meaningful incremental reimbursement. He keeps an Underweight rating on the shares with a $19 price target.
12/11/17
PIPR
12/11/17
NO CHANGE
PIPR
Overweight
Piper says CMS coding edits could negatively impact Myriad Genetics
The Centers for Medicare and Medicaid Services made an edit to its procedure guidelines, essentially stating labs should use code 81162, instead of combining 81211 and 81213, Piper Jaffray analyst William Quirk tells investors in a research note. The analyst believes Myriad Genetics bills BRCA tests using the two codes. As such, the edit by CMS could have financial implications for the company as 81162 is paid 21% lower than the combined 81211/81213 rate, Quirk points out. He notes, however, that Myriad management states these coding edits were expected and already factored into guidance. Quirk believes the company's outlook for the second half of 2018 "appears low enough," but he notes that this is the first he's heard about the CMS change. He has a Neutral rating on Myriad with a $29 price target. The stock in morning trading is down 3% to $32.66.
01/29/18
GSCO
01/29/18
INITIATION
Target $32
GSCO
Sell
Myriad Genetics initiated with a Sell at Goldman Sachs
Goldman analyst Patrick Donnelly initiated Myriad Genetics with a Sell and $32 price target citing "extended" valuation and excess optimism around GeneSight reimbursement.
11/02/17
PIPR
11/02/17
NO CHANGE
PIPR
Neutral
Myriad trial hit two important secondary endpoints, says Piper Jaffray
Piper Jaffray analyst William Quirk notes shares of Myriad Genetics are sinking after its key growth asset GeneSight missed the primary endpoint from a large, double blind clinical trial. The study, though, hit two important secondary endpoints that may have a positive impact on longer-term private payer coverage, Quirk tells investors in a research note. The analyst believes the secondary endpoints "may prove to be more important for driving future revenue growth." He keeps a Neutral rating on shares of Myriad Genetics.
SFIX Stitch Fix
$24.12

1.55 (6.87%)

12/12/17
WBLR
12/12/17
INITIATION
WBLR
Outperform
Stitch Fix initiated with an Outperform at William Blair
William Blair started Stitch Fix with an Outperform rating.
12/12/17
RBCM
12/12/17
INITIATION
Target $29
RBCM
Outperform
Stitch Fix initiated with an Outperform at RBC Capital
RBC Capital analyst Mark Mahaney initiated Stitch Fix with an Outperform rating and a price target of $29. Mahaney says the company is "revolutionizing fashion", using data science and personal stylists in its offerings of direct shipments of apparel to clients' homes. The analyst believes the company can expand its client base from 2M to 4M over the next 3 years as it ramps up its category expansion.
12/12/17
12/12/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mylan (MYL), Teva (TEVA) and Endo (ENDP) initiated with a Neutral at Gugenheim, while Impax (IPXL) was initiated with a Buy. 2. Stitch Fix (SFIX) initiated with an Outperform at William Blair, a Neutral at JPMorgan and Goldman Sachs, an Overweight at Piper Jaffray, an Equal Weight at Barclays and a Hold at Stifel. 3. Exxon Mobil (XOM) and ConocoPhillips (COP) initiated with a Neutral at Credit Suisse. The firm also started Range Resources (RRC) and Anadarko (APC) with an Outperform, and Laredo Petroleum (LPI), Energen (EGN), Southwestern Energy (SWN), Noble Energy (NBL), Murphy Oil (MUR), Cabot Oil & Gas (COG) and Newfield Exploration (NFX) with a Neutral rating. 4. Restaurant Brands (QSR) initiated with an Outperform at Evercore ISI. 5. Waste Connections (WCN) initiated with an Outperform, named a top pick at BMO Capital. This list is just a portion of The Fly's full analyst coverage. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/17
PIPR
12/20/17
NO CHANGE
Target $29
PIPR
Overweight
Piper keeps Overweight on Stitch Fix amid post-earnings selloff
Piper Jaffray analyst Erinn Murphy keeps an Overweight rating on Stitch Fix with a $29 price target with the stock down 12% following last night's Q1 results. The analyst attributes the selloff to the EBITDA range given for fiscal 2018, noting the company could opportunistically investment more throughout the year. She notes, though, that the company's sales guidance was even better than the 20% the Street had modeled in Q2-Q4. Murphy raised her revenue estimates following management's guidance.

TODAY'S FREE FLY STORIES

TME

Tencent Music

$0.00

(0.00%)

19:33
12/11/18
12/11
19:33
12/11/18
19:33
Syndicate
Tencent Music 82M share IPO priced at $13.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TME

Tencent Music

$0.00

(0.00%)

19:26
12/11/18
12/11
19:26
12/11/18
19:26
Syndicate
Breaking Syndicate news story on Tencent Music »

Tencent Music prices IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CRM

Salesforce

$136.83

-0.46 (-0.34%)

19:25
12/11/18
12/11
19:25
12/11/18
19:25
Conference/Events
Salesforce management to meet with Goldman Sachs »

Alex Dayon, President and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 19

    Dec

  • 20

    Dec

  • 03

    Mar

O

Realty Income

$66.30

0.58 (0.88%)

19:06
12/11/18
12/11
19:06
12/11/18
19:06
Hot Stocks
Realty Income raises monthly dividend to 22.1c per share from 22.05c »

Realty Income Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKH

Black Hills

$67.28

0.06 (0.09%)

19:02
12/11/18
12/11
19:02
12/11/18
19:02
Hot Stocks
Black Hills buys 50% interest in Busch Ranch I Wind Farm »

Black Hills Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXNX

Axonics

$15.66

-0.36 (-2.25%)

, PVTL

Pivotal Software

$17.80

-0.23 (-1.28%)

18:59
12/11/18
12/11
18:59
12/11/18
18:59
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

AXNX

Axonics

$15.66

-0.36 (-2.25%)

PVTL

Pivotal Software

$17.80

-0.23 (-1.28%)

HAIN

Hain Celestial

$18.80

-0.38 (-1.98%)

URI

United Rentals

$101.89

0.02 (0.02%)

VKTX

Viking Therapeutics

$9.47

0.01 (0.11%)

FSLR

First Solar

$42.43

-0.79 (-1.83%)

JAZZ

Jazz Pharmaceuticals

$140.46

0.9 (0.64%)

SEIC

SEI Investments

$48.50

-0.64 (-1.30%)

BEN

Franklin Resources

$31.53

-0.52 (-1.62%)

PLAY

Dave & Buster's

$51.08

-1.44 (-2.74%)

AEO

American Eagle

$19.03

-0.49 (-2.51%)

ARWR

Arrowhead

$13.61

-0.05 (-0.37%)

MRNS

Marinus Pharmaceuticals

$5.10

-0.14 (-2.67%)

FLDM

Fluidigm

$7.58

-0.11 (-1.43%)

TOCA

Tocagen

$12.85

0.2 (1.58%)

LAND

Gladstone Land

$13.33

-0.16 (-1.19%)

ANGI

Angi Homeservices

$16.62

-0.11 (-0.66%)

BAC

Bank of America

$24.58

-0.17 (-0.69%)

MS

Morgan Stanley

$40.62

-0.07 (-0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 13

    Dec

  • 13

    Dec

  • 14

    Dec

  • 14

    Dec

  • 19

    Dec

  • 20

    Dec

  • 20

    Dec

  • 12

    Feb

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 13

    Dec

EW

Edwards Lifesciences

$163.20

1.2 (0.74%)

, BSX

Boston Scientific

$36.55

0.41 (1.13%)

18:47
12/11/18
12/11
18:47
12/11/18
18:47
Hot Stocks
Edwards says does not expect to pay $35M award in Boston Scientific case »

Edwards Lifesciences (EW)…

EW

Edwards Lifesciences

$163.20

1.2 (0.74%)

BSX

Boston Scientific

$36.55

0.41 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RARX

RA Pharmaceuticals

$15.97

-1.61 (-9.16%)

18:41
12/11/18
12/11
18:41
12/11/18
18:41
Syndicate
RA Pharmaceuticals 8.4M share Secondary priced at $15.50 »

Jefferies, BMO Capital,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

HTLF

Heartland Financial

$49.30

-0.24 (-0.48%)

18:38
12/11/18
12/11
18:38
12/11/18
18:38
Hot Stocks
Heartland Financial announces special cash dividend of 5c »

Heartland Financial USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANGI

Angi Homeservices

$16.62

-0.11 (-0.66%)

18:24
12/11/18
12/11
18:24
12/11/18
18:24
Syndicate
Angi Homeservices 1.5M share Spot Secondary priced at $16.40 »

The deal priced within…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SPY

SPDR S&P 500 ETF Trust

$264.13

0.04 (0.02%)

, SPX

S&P 500

$0.00

(0.00%)

18:24
12/11/18
12/11
18:24
12/11/18
18:24
Periodicals
Huawei CFO Meng granted bail by Canadian judge, Bloomberg reports »

Huawei Technologies Co.…

SPY

SPDR S&P 500 ETF Trust

$264.13

0.04 (0.02%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$36.55

0.41 (1.13%)

, EW

Edwards Lifesciences

$163.20

1.2 (0.74%)

18:14
12/11/18
12/11
18:14
12/11/18
18:14
Hot Stocks
Boston Scientific says it 'prevails' in U.S. Edwards Lifesciences litigation »

Boston Scientific (BSX)…

BSX

Boston Scientific

$36.55

0.41 (1.13%)

EW

Edwards Lifesciences

$163.20

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

MSFT

Microsoft

$108.67

1.11 (1.03%)

18:14
12/11/18
12/11
18:14
12/11/18
18:14
Hot Stocks
Microsoft CMO Chris Capossela sells 4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

GLD

SPDR Gold Shares

$117.55

-0.13 (-0.11%)

18:05
12/11/18
12/11
18:05
12/11/18
18:05
Hot Stocks
SPDR Gold Shares holdings rise to 763.56MT from 760.32MT »

This is the third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$264.13

0.04 (0.02%)

, SPX

S&P 500

$0.00

(0.00%)

18:04
12/11/18
12/11
18:04
12/11/18
18:04
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

Huawei CFO Meng granted…

SPY

SPDR S&P 500 ETF Trust

$264.13

0.04 (0.02%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIEGY

Siemens

$0.00

(0.00%)

17:56
12/11/18
12/11
17:56
12/11/18
17:56
Periodicals
Siemens to close Texas turbines facility, dismiss 200 workers, Reuters says »

Siemens intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CABO

Cable One

$871.98

9.68 (1.12%)

17:56
12/11/18
12/11
17:56
12/11/18
17:56
Hot Stocks
Cable One to rebrand as Sparklight in the summer of 2019 »

Cable One announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJRD

Aerojet Rocketdyne

$35.40

0.02 (0.06%)

17:53
12/11/18
12/11
17:53
12/11/18
17:53
Hot Stocks
Aerojet Rocketdyne awarded DARPA contract to design OpFires propulsion system »

Aerojet Rocketdyne said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGNC

AGNC Investment

$17.92

0.045 (0.25%)

17:45
12/11/18
12/11
17:45
12/11/18
17:45
Hot Stocks
AGNC Investment reports tangible net book value of $16.76 per share »

AGNC Investment …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$120.40

-0.47 (-0.39%)

, PCRFY

Panasonic

$0.00

(0.00%)

17:40
12/11/18
12/11
17:40
12/11/18
17:40
Periodicals
Breaking Periodicals news story on Toyota, Panasonic »

Panasonic to supply…

TM

Toyota

$120.40

-0.47 (-0.39%)

PCRFY

Panasonic

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDAQ

Nasdaq

$87.28

0.08 (0.09%)

17:37
12/11/18
12/11
17:37
12/11/18
17:37
Hot Stocks
Nasdaq acquires Quandl to 'advance' the use of alternative data »

Nasdaq announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KL

Kirkland Lake Gold

$24.36

0.58 (2.44%)

17:36
12/11/18
12/11
17:36
12/11/18
17:36
Hot Stocks
Kirkland Lake Gold raises dividend to C$0.04 from C$0.03 »

Kirkland Lake Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$36.55

0.41 (1.13%)

, EW

Edwards Lifesciences

$163.20

1.2 (0.74%)

17:26
12/11/18
12/11
17:26
12/11/18
17:26
Periodicals
Breaking Periodicals news story on Boston Scientific, Edwards Lifesciences »

Boston Scientific wins…

BSX

Boston Scientific

$36.55

0.41 (1.13%)

EW

Edwards Lifesciences

$163.20

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

HUSA

Houston American Energy

$0.22

0.0009 (0.42%)

17:26
12/11/18
12/11
17:26
12/11/18
17:26
Syndicate
Breaking Syndicate news story on Houston American Energy »

Houston American Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTVT

vTv Therapeutics

$1.86

0.02 (1.09%)

17:18
12/11/18
12/11
17:18
12/11/18
17:18
Hot Stocks
vTv Therapeutics initiates restructuring, will cut roughly 65% of workforce »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.